Carotid stenting

InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

Retrieved on: 
Wednesday, August 4, 2021
Neurosurgery, Vascular surgery, Carotid stenting, Micronet, Stroke

A telephonic replay of the call will be available through August 24, 2021 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10158721.

Key Points: 
  • A telephonic replay of the call will be available through August 24, 2021 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10158721.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

Retrieved on: 
Friday, July 23, 2021
Medical specialties, Medicine, Clinical medicine, Vascular diseases, Neurosurgery, Vascular surgery, Carotid stenting, Interventional radiology, Carotid artery stenosis, Stent, Restenosis, Angioplasty

The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .

Key Points: 
  • The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .
  • These are the first of 315 patients who are expected to be enrolled in the trial and treated with CGuard EPS in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting.
  • I believe that the initiation of this trial marks an important milestone for the potential approval of CGuard EPS and the potential of CGuard EPS in advancing the treatment of CAD and stroke prevention, commented Dr. Metzger.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Ballad Health hosts first United States clinical trials of CGuard Embolic Protection System

Retrieved on: 
Thursday, July 22, 2021
Medicine, Carotid stenting, Neurosurgery, Vascular surgery, Stroke, Preventive healthcare, Health sciences, Health care

KINGSPORT, Tenn., July 22, 2021 (GLOBE NEWSWIRE) -- Ballad Health is leading a new clinical trial in the United States for a potentially groundbreaking new carotid stent.

Key Points: 
  • KINGSPORT, Tenn., July 22, 2021 (GLOBE NEWSWIRE) -- Ballad Health is leading a new clinical trial in the United States for a potentially groundbreaking new carotid stent.
  • Ballad Health is committed to advancing medical science that has the potential to improve the human condition, said Ballad Health Chairman and Chief Executive Officer Alan Levine.
  • The Appalachian Highlands is leading the United States in bringing what could be the next big breakthrough in stroke prevention.
  • 2 enroller in the United States and globally in at least 30 top research trials, and it is now leading trials for CGuard.

First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting

Medical specialties, Medicine, Surgery, Vascular surgery, Vascular diseases, TCAR, Society for Vascular Surgery, Atherosclerosis, Stroke, Neurosurgery, Carotid stenting

Retrospective data for symptomatic and asymptomatic standard risk patients undergoing CEA and TCAR for atherosclerotic carotid disease was reviewed to show TCAR and CEA have equivalent risk of perioperative stroke, death, or MI and ipsilateral stroke through 1 year.

Key Points: 
  • Retrospective data for symptomatic and asymptomatic standard risk patients undergoing CEA and TCAR for atherosclerotic carotid disease was reviewed to show TCAR and CEA have equivalent risk of perioperative stroke, death, or MI and ipsilateral stroke through 1 year.
  • We are thrilled to have this ground-breaking analysis presented at VAM, the preeminent annual Vascular Surgery conference.
  • In addition to this presentation, Silk Road Medical will be hosting TCAR @ Vascular Live at the Vascular Annual Meeting on Friday, August 20 from 3:05-3:30 p.m. PDT in Exhibit Hall B1.
  • Silk Road Medical will be exhibiting at the Society for Vascular Surgerys Vascular Annual Meeting in booth #401.

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

Retrieved on: 
Friday, May 14, 2021
Medical specialties, Neurosurgery, Vascular surgery, Finance, Carotid artery stenosis, Carotid stenting, Clinical medicine, Stroke, Ticker symbol, New York Stock Exchange, Carotid artery

b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Clinical medicine, Medicine, Stroke, Carotid artery

b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

InspireMD Provides Corporate Update for Shareholders

Retrieved on: 
Monday, April 19, 2021
Medical specialties, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Clinical medicine, Carotid artery, Medicine

Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.

Key Points: 
  • Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.
  • We believe that moving to the Nasdaq Capital Market is a strategically sound approach that places us in the company of our peers and allows for improved visibility in the market.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization

Medical specialties, Medicine, Clinical medicine, Neurosurgery, Vascular surgery, TCAR, Carotid stenting, Aging-associated diseases, Carotid endarterectomy, Interventional radiology, Endarterectomy, Stroke

The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).

Key Points: 
  • The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or death at 30 days after carotid revascularization, whether TCAR or carotid endarterectomy (CEA).
  • We believe this indicates that centers that offer TCAR are able to better align patients with the best procedure for their individual clinical and anatomic characteristics.
  • The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure.
  • The companys flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021
Medical specialties, Angiology, Cardiovascular system, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Carotid artery stenosis, Stroke, Carotid artery, Carotid endarterectomy

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.